Futibatinib was studied in a phase I trial that recruited 197 patients with previously-treated advanced solid tumors, 83 of which had CCA with a mutation, fusion, or amplification of FGFR2 (NCT02052778) [92]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.